×
It looks like you're using an obsolete version of internet explorer. Internet explorer is no longer supported by Microsoft since the end of 2015. We invite you to use a newer browser such as Firefox, Google Chrome or Microsoft Edge.
My Player placeholder

Become an Oncostream member and receive full access to its content!

You must be an Oncostream member to access videos without any restrictions. Register for free in one minute and access all services provided by Oncostream.You will also be able to log into Oncostream from your Facebook or twitter account by clicking on login on the top-right corner of Oncostream website.

Registration Login


Worldwide schedules comment Share
18:00
Introduction
Dr Leïla Bengrine-Lefevre
18:05
Les nouvelles recommandations St-Paul-de-Vence appliquées en vraie vie:
  • Cas clinique d’une patiente en première ligne d’un cancer de l’ovaire avancé
    Dr Fernando Bazan
     
  • Cas Clinique d’une patiente en rechute d’un cancer de l’ovaire avancé
    Dr Leïla Bengrine-Lefevre
19:05
Défauts de la recombinaison homologue (HRD):  définition et perspectives thérapeutiques
Dr Elisabeth Luporsi
19:25
La chirurgie à l’ère des PARP Inhibiteurs
Pr Chérif Akladios
19:55 Conclusion

 

Shooting date : 2021-07-12
Last update : 2021-12-23
1 comment
Join the Discussion
  • mohamed S. merci

      Please, select your files, click upload button, write your comment and click the send button. (allowed formats : images jpeg, gif, png, and PDF)
      Your browser doesn't have Flash, Silverlight or HTML5 support.


    Suggestions

    Tuesday, March 22nd 2022 from 07pm to 08:50pm (GMT+1)
    Honolulu : Tuesday, March 22nd 2022 from 07am to 08:50am (GMT+1)
    San Francisco : Tuesday, March 22nd 2022 from 09am to 10:50am (GMT+1)
    New York : Tuesday, March 22nd 2022 from 12pm to 01:50pm (GMT+1)
    Buenos Aires : Tuesday, March 22nd 2022 from 02pm to 03:50pm (GMT+1)
    London / Dublin : Tuesday, March 22nd 2022 from 05pm to 06:50pm (GMT+1)
    Paris / Berlin : Tuesday, March 22nd 2022 from 06pm to 07:50pm (GMT+1)
    Istanbul : Tuesday, March 22nd 2022 from 07pm to 08:50pm (GMT+1)
    Moscou / Dubaï : Tuesday, March 22nd 2022 from 09pm to 10:50pm (GMT+1)
    Bangkok : Wednesday, March 23rd 2022 from 12am to 01:50am (GMT+1)
    Shanghai : Wednesday, March 23rd 2022 from 01am to 02:50am (GMT+1)
    Tokyo : Wednesday, March 23rd 2022 from 02am to 03:50am (GMT+1)
    Sydney : Wednesday, March 23rd 2022 from 03am to 04:50am (GMT+1)
    Wellington : Wednesday, March 23rd 2022 from 05am to 06:50am (GMT+1)

    Cancer de l’ovaire

    Cycle de formation en oncologie gynécologique et sénologique de l’Institut Curie

    Share
    Monday, April 28th 2025 from 06:30pm to 07:30pm (GMT+2)
    Honolulu : Monday, April 28th 2025 from 06:30am to 07:30am (GMT+2)
    San Francisco : Monday, April 28th 2025 from 09:30am to 10:30am (GMT+2)
    New York : Monday, April 28th 2025 from 12:30pm to 01:30pm (GMT+2)
    Buenos Aires : Monday, April 28th 2025 from 01:30pm to 02:30pm (GMT+2)
    Reykjavik : Monday, April 28th 2025 from 04:30pm to 05:30pm (GMT+2)
    London / Dublin : Monday, April 28th 2025 from 05:30pm to 06:30pm (GMT+2)
    Paris / Berlin : Monday, April 28th 2025 from 06:30pm to 07:30pm (GMT+2)
    Istanbul : Monday, April 28th 2025 from 07:30pm to 08:30pm (GMT+2)
    Moscou / Dubaï : Monday, April 28th 2025 from 08:30pm to 09:30pm (GMT+2)
    Bangkok : Monday, April 28th 2025 from 11:30pm to 12:30am (GMT+2)
    Shanghai : Tuesday, April 29th 2025 from 12:30am to 01:30am (GMT+2)
    Tokyo : Tuesday, April 29th 2025 from 01:30am to 02:30am (GMT+2)
    Sydney : Tuesday, April 29th 2025 from 03:30am to 04:30am (GMT+2)
    Wellington : Tuesday, April 29th 2025 from 05:30am to 06:30am (GMT+2)

    PARPi dans le cancer de l'ovaire en 1L

    Données actuelles et perspectives pour la combinaison avec l’IO

    Share
    Monday, September 25th 2023 from 06:30pm to 08pm (GMT+2)
    Honolulu : Monday, September 25th 2023 from 06:30am to 08am (GMT+2)
    San Francisco : Monday, September 25th 2023 from 09:30am to 11am (GMT+2)
    New York : Monday, September 25th 2023 from 12:30pm to 02pm (GMT+2)
    Buenos Aires : Monday, September 25th 2023 from 01:30pm to 03pm (GMT+2)
    Reykjavik : Monday, September 25th 2023 from 04:30pm to 06pm (GMT+2)
    London / Dublin : Monday, September 25th 2023 from 05:30pm to 07pm (GMT+2)
    Paris / Berlin : Monday, September 25th 2023 from 06:30pm to 08pm (GMT+2)
    Istanbul : Monday, September 25th 2023 from 07:30pm to 09pm (GMT+2)
    Moscou / Dubaï : Monday, September 25th 2023 from 08:30pm to 10pm (GMT+2)
    Bangkok : Monday, September 25th 2023 from 11:30pm to 01am (GMT+2)
    Shanghai : Tuesday, September 26th 2023 from 12:30am to 02am (GMT+2)
    Tokyo : Tuesday, September 26th 2023 from 01:30am to 03am (GMT+2)
    Sydney : Tuesday, September 26th 2023 from 03:30am to 05am (GMT+2)
    Wellington : Tuesday, September 26th 2023 from 05:30am to 07am (GMT+2)

    Les scores indispensables dans la prise en charge des cancers de l'ovaire

    Cycle d'enseignement - Les cancers gynécologiques

    Share
    Thursday, March 14th 2024 from 06pm to 07:30pm (GMT+1)
    Honolulu : Thursday, March 14th 2024 from 06am to 07:30am (GMT+1)
    San Francisco : Thursday, March 14th 2024 from 08am to 09:30am (GMT+1)
    New York : Thursday, March 14th 2024 from 11am to 12:30pm (GMT+1)
    Buenos Aires : Thursday, March 14th 2024 from 01pm to 02:30pm (GMT+1)
    London / Dublin : Thursday, March 14th 2024 from 04pm to 05:30pm (GMT+1)
    Paris / Berlin : Thursday, March 14th 2024 from 05pm to 06:30pm (GMT+1)
    Istanbul : Thursday, March 14th 2024 from 06pm to 07:30pm (GMT+1)
    Moscou / Dubaï : Thursday, March 14th 2024 from 08pm to 09:30pm (GMT+1)
    Bangkok : Thursday, March 14th 2024 from 11pm to 12:30am (GMT+1)
    Shanghai : Friday, March 15th 2024 from 12am to 01:30am (GMT+1)
    Tokyo : Friday, March 15th 2024 from 01am to 02:30am (GMT+1)
    Sydney : Friday, March 15th 2024 from 02am to 03:30am (GMT+1)
    Wellington : Friday, March 15th 2024 from 04am to 05:30am (GMT+1)

    Prise en charge du cancer de l’ovaire en L1 en région Nord/Normandie : où en sommes-nous ?

    Cycle d'enseignement sur le cancer de l'ovaire - Troisième session

    Share
    Scroll Up